Enliven Therapeutics (ELVN) News Today → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free ELVN Stock Alerts $17.18 +0.40 (+2.38%) (As of 04/26/2024 06:55 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCommit To Purchase Enliven Therapeutics At $10, Earn 11.2% Annualized Using Optionsnasdaq.com - April 28 at 10:04 AMFinancial Survey: Enliven Therapeutics (NASDAQ:ELVN) vs. Processa Pharmaceuticals (NASDAQ:PCSA)americanbankingnews.com - April 28 at 4:10 AMBuy Rating Affirmed for Apellis Pharmaceuticals Amid Positive Outlook and Growth Potentialmarkets.businessinsider.com - April 26 at 5:23 PMBuy Rating Affirmed: Enliven Therapeutics’ ELVN-001 Shows Market Potential and Efficacy in Resistant Patientsmarkets.businessinsider.com - April 26 at 7:22 AMEnliven Therapeutics (NASDAQ:ELVN) Sees Strong Trading Volumeamericanbankingnews.com - April 21 at 5:46 AMMasterCraft Boat, SentinelOne, and More Stocks See Action From Activist Investorsfinance.yahoo.com - April 19 at 3:21 PMEnliven Therapeutics (NASDAQ:ELVN) Sees Large Volume Increasemarketbeat.com - April 19 at 2:56 PMEnliven Therapeutics files to sell 6.43M shares for holdersmsn.com - April 18 at 10:31 PMEnliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher marketbeat.com - April 18 at 1:56 PMEnliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02msn.com - April 17 at 9:16 PMEnliven Therapeutics CMO sells $501k in company stockinvesting.com - April 16 at 10:49 PMEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Richard A. Heyman Sells 1,270 Sharesinsidertrades.com - April 16 at 6:24 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $25,387.30 in Stockinsidertrades.com - April 16 at 4:46 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 1,270 Shares of Stockmarketbeat.com - April 15 at 9:40 PMEnliven Therapeutics (NASDAQ:ELVN) Shares Down 3.6% After Insider Sellingmarketbeat.com - April 15 at 10:35 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 53,400 Shares of Stockinsidertrades.com - April 13 at 7:07 AMEnliven reports promising Phase 1 data for leukemia druginvesting.com - April 12 at 10:46 PMStrong Buy Rating for Enliven Therapeutics’ ELVN-001 Following Outstanding Phase 1 Results and Market Potentialmarkets.businessinsider.com - April 11 at 10:55 PMEnliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Programfinance.yahoo.com - April 11 at 5:50 PMEnliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursdaymsn.com - April 11 at 12:46 PMEnliven Therapeutics Shares Hit 52-Week High After Positive Proof of Concept Data for Blood Cancer Drugmarketwatch.com - April 11 at 12:46 PMEnliven Therapeutics shares rise on promising preliminary data for blood cancer drugproactiveinvestors.com - April 11 at 12:25 PMEnliven Therapeutics (NASDAQ:ELVN) Sets New 52-Week High at $26.00marketbeat.com - April 11 at 10:45 AMEnliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemiaglobenewswire.com - April 11 at 7:55 AMEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 4,875 Sharesinsidertrades.com - April 11 at 6:48 AMEnliven Therapeutics (NASDAQ:ELVN) Stock Price Up 3.5%marketbeat.com - April 10 at 3:24 PMEnliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Saysmarkets.businessinsider.com - April 9 at 6:56 PMEnliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directorsglobenewswire.com - April 9 at 4:05 PMOwning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN),finance.yahoo.com - April 9 at 8:55 AMMizuho Begins Coverage on Enliven Therapeutics (NASDAQ:ELVN)marketbeat.com - April 9 at 8:23 AMRahul D. Ballal Sells 3,485 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockinsidertrades.com - April 9 at 4:46 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,485 Shares of Stockmarketbeat.com - April 8 at 9:21 PMEnliven Therapeutics (NASDAQ:ELVN) Trading Down 3.9%marketbeat.com - April 8 at 1:46 PMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells 3,237 Shares of Stockinsidertrades.com - April 4 at 6:50 AMRahul D. Ballal Sells 3,237 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockmarketbeat.com - April 4 at 12:21 AMEnliven Therapeutics (NASDAQ:ELVN) Trading 5.3% Higher marketbeat.com - April 1 at 3:29 PMBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stockinsidertrades.com - March 31 at 5:56 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 3,250 Shares of Stockmarketbeat.com - March 29 at 6:48 PMEnliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024globenewswire.com - March 28 at 4:05 PMEnliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Samuel Kintz Sells 12,000 Sharesinsidertrades.com - March 28 at 8:33 AMInsider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 12,000 Shares of Stockmarketbeat.com - March 27 at 6:42 PMEnliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $18,415.00 in Stockmarketbeat.com - March 21 at 7:58 PMEnliven Therapeutics (NASDAQ:ELVN) Shares Down 5.3% marketbeat.com - March 21 at 5:42 PMEnliven Therapeutics, Inc.: Enliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updatesfinanznachrichten.de - March 19 at 11:26 AMEnliven Therapeutics announces $90M private placement to fund R&D activitiesmsn.com - March 19 at 11:26 AMEnliven Therapeutics Announces $90 Million Private Placement Financing and Provides Pipeline Updatesglobenewswire.com - March 19 at 8:30 AMEnliven Therapeutics (NASDAQ:ELVN) Trading Up 3.1%marketbeat.com - March 18 at 11:26 AMTD Cowen Sticks to Their Buy Rating for Enliven Therapeutics (ELVN)markets.businessinsider.com - March 15 at 2:52 AMELVN Stock Earnings: Enliven Therapeutics Beats EPS for Q4 2023investorplace.com - March 14 at 10:04 PMEnliven Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Updateglobenewswire.com - March 14 at 4:05 PM Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Healthcare Takes A Big Step Forward With The Help Of AI (Ad)The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+. Click here to see why this small company is trusted by the Mayo Clinic ELVN Media Mentions By Week ELVN Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ELVN News Sentiment▼0.260.34▲Average Medical News Sentiment ELVN News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ELVN Articles This Week▼51▲ELVN Articles Average Week Get Enliven Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ARS Pharmaceuticals News Today Tango Therapeutics News Today Arcutis Biotherapeutics News Today Sage Therapeutics News Today 89bio News Today ALX Oncology News Today Tyra Biosciences News Today OPKO Health News Today Pliant Therapeutics News Today Arcturus Therapeutics News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ELVN) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsBiden out June 13; Kamala won’t replace him?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmithThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
